bluuebunny/crossref_metadata_2025_split huggingface dataset:
72-LB: The T1DLoCHO Study: Effects of a Low-Carbohydrate, Nonketogenic Diet vs. Standard Diabetes Diet on Glycemic Control in Young Adults with Type 1 Diabetes
Authors: CROWDER CHRISTINA M. , JELLEY DAVID , CONDREN MICHELLE , CHALMERS LAURA , GRAEF JENNIFER L. 
Published: June 2019

While standard of care medical nutrition therapy for type 1 diabetes (T1D) centers on matching carbohydrate to insulin at meals, recent literature has shown superior glycemic control and cardiovascular measures with lower carbohydrate dietary patterns (&lt;130g/day) compared to the standard MyPlate (50% total calories as carbohydrate) approach.
Aims: To determine if a 60-80 g CHO (LC) per day diet leads to improved glycemic control, cardiovascular, and inflammatory markers compared to the standard of care (SOC) (&gt; 150 g CHO per day).
Methods: Participants (age 18-30) with T1D on insulin pump therapy were recruited from an endocrinology practice from May through December, 2018. Glycemic variability (continuous glucose monitor derived time in range (TIR), 70-180 mg/dL and hemoglobin A1c), total cholesterol, HDL, LDL, triglycerides (TRIG), and LDL particle number, and nutrient intake were assessed using a randomized cross over design with 12 week interventions of LC and SOC. An 8-week washout period was employed between interventions.
Preliminary Results: Expressed Mean(SD). 11 subjects started the study and 5 withdrew due to noncompliance. Of the first 4 patients to finish the LC arm, mean TIR increased from 62.2 (16 .2) to 65.7 (16.2) %, + 3.5 (13.4)%; A1c decreased from 7.1 (0.6) to 6.7 (0.6), -0.5% (0.2); Total Cholesterol decreased from 186.3 (7.2) to 172.0 (25.7) mg/dL; LDL decreased from 104.8 (25.7) to 85.0 (9.2) mg/dL; HDL increased from 63.5 (21.9) to 69.8 (25.5) mg/dL; TRIG decreased from 89.5 (14.9) to 75.8 (21.4) mg/dL; LDL Particle number decreased from 1233.7 (286.6) to 1008.3 (61.5) nmol/L. Of the first 3 patients to finish SOC, no significant differences were seen.
Conclusion: These preliminary results are encouraging, demonstrating that LC is associated with trends towards improvements in glycemic control (TIR and A1c) without deleterious effects on lipids. Larger more robust studies are needed for further exploration.

Disclosure
C.M. Crowder: None. D. Jelley: Research Support; Self; AbbVie Inc., AstraZeneca, Novo Nordisk Inc. M. Condren: None. L. Chalmers: None. J.L. Graef: None.

Funding
University of Oklahoma Health Sciences Center; Harold Hamm Diabetes Center; OU-TU School of Community Medicine; Dexcom, Inc.
725-P: Reducing Hypoglycemic Risk during Postprandial Exercise with Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes: Announced and Unannounced Exercise
Authors: TAGOUGUI SEMAH , TALEB NADINE , SUPPERE CORINNE , BOUKABOUS INÈS , MESSIER VIRGINIE , RABASA-LHORET RÉMI 
Published: June 2019

Background: Exercise-induced hypoglycemia is a major barrier for physical activity practice. Compared to conventional insulin therapy, closed-loop (CL) insulin delivery reduces hypoglycemic risk during post-absorptive exercise but has not been studied during postprandial exercise.
Methods: Randomized crossover trial comparing 3 strategies for a postprandial (PP) exercise (90 min after breakfast) at 60% of VO2peak for 60min: 1) Unannounced exercise (Unann); 2) Announced exercise with reduced insulin bolus (Ann+RB): increased glucose target combined with a 33% meal bolus reduction); 3) Announced exercise with full bolus (Ann+FB): increased glucose target combined with usual meal bolus in 37 adults with type 1 diabetes.
Results: Median percentage time spent in hypoglycemia (&lt;70 mg/dl) was reduced with Ann+RB compared to Unann (Primary outcome; 0[0-0]% vs. 0[0-26]%; p&lt;0.05). The drop in plasma glucose during exercise was smaller with Ann+RB (-5.5 ± 50.5 than with Ann+FB (-46.8 ± 52.2) and Unann (-43.2 ± 48.6) strategies (p &lt;0.05). Accordingly, hypoglycemic events were reduced with Ann+RB (n=2) compared to Ann+FB (n=3) and Unann (n=9). However, Ann+BR strategy was associated with increased time in hyperglycemia (&gt; 250mg/dl).
Conclusion: Announcement of postprandial exercise to the closed-loop algorithm combined with meal bolus reduction reduced hypoglycemic risk, yet at the expense of mild increase in hyperglycemia.

Disclosure
S. Tagougui: None. N. Taleb: None. C. Suppere: None. I. Boukabous: None. V. Messier: Other Relationship; Self; Eli Lilly and Company. R. Rabasa-Lhoret: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S.
734-P: Perceived Barriers to Physical Activity in People with Type 1 Diabetes Using CGM
Authors: ANDRE CAMILLE C. , KUDVA YOGISH C. , DADLANI VIKASH , CESCON MARZIA , MCCRADY-SPITZER SHELLY K. , CHURCH MEI MEI , REID COREY , KUMARI KANCHAN , CHOUDHARY DIVYA , DOYLE FRANCIS J. , DASSAU EYAL , PINSKER JORDAN E. 
Published: June 2019

Objective: Prior reports using the validated Barriers to Physical Activity in Diabetes (type 1) [BAPAD1] scale showed fear of hypoglycemia was the strongest barrier to regular physical activity (PA) in people with type 1 diabetes (T1D). This was before the higher prevalence of continuous glucose monitoring (CGM) use today.
Methods: Twenty adults with T1D enrolling in an exercise tracking study completed the BAPAD1, reporting perceived barriers to regular PA on a scale of 1 (extremely unlikely) to 7 (extremely likely). All used insulin pumps. Fifteen of the 20 were current CGM users.
Results: Baseline characteristics were age 44.9±15.0 years, F/M 12/8, HbA1c 6.8±0.7%, and diabetes duration 22.9±15.9 years. Mean BAPAD1 score was 2.55±1.05. The highest scores were for risk of hypoglycemia (4.00±1.78) and work schedule (3.70±2.00), with current CGM users reporting higher overall scores than non-CGM users (2.71±1.04 vs. 2.10±1.07, p=0.28). Significantly higher scores were reported by CGM users for “The fear of being tired” (p=0.01), “The fact that you have diabetes” (p=0.03), and “The location of a gym” (p=0.04) (Table 1). Greater barrier scores for work schedule were associated with lower age (r=-0.5, p=0.02).
Conclusions: CGM use was not associated with lower perceived barriers to regular PA, suggesting additional interventions beyond providing ways to measure glucose are needed to reduce these barriers in people with T1D.

Disclosure
C.C. Andre: None. Y.C. Kudva: Advisory Panel; Self; Novo Nordisk Inc. Other Relationship; Self; Dexcom, Inc., Roche Diabetes Care, Tandem Diabetes Care. V. Dadlani: None. M. Cescon: None. S.K. McCrady-Spitzer: None. M. Church: None. C. Reid: None. K. Kumari: None. D. Choudhary: None. F.J. Doyle: Consultant; Self; ModeAGC. Other Relationship; Self; Insulet Corporation. E. Dassau: Consultant; Self; Eli Lilly and Company, Insulet Corporation. Research Support; Self; Dexcom, Inc., DreaMed Diabetes, Ltd., Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Xeris Pharmaceuticals, Inc. Speaker's Bureau; Self; Roche Diabetes Care. Other Relationship; Self; ModAGC. J.E. Pinsker: Research Support; Self; Ascensia Diabetes Care, Dexcom, Inc., Insulet Corporation, LifeScan, Inc., Roche Diabetes Care, Tandem Diabetes Care. Speaker's Bureau; Self; Tandem Diabetes Care.

Funding
JDRF; The Leona M. and Harry B. Helmsley Charitable Trust (2-SRA-2017-503-M-B); Dexcom, Inc. (IIS-2017-043)
737-P: Physical Activity Levels among Latino Adults with Type 2 Diabetes
Authors: BEVIER WENDY C. , GLANTZ NAMINO M. , HOPPE CHARIS B. , MORALES JESSIKAH , LAREZ ARIANNA J. , CONNEELY MARY M. , CHEN KONG Y. , KERR DAVID 
Published: June 2019

Physical activity (PA) is a cornerstone of type 2 diabetes (T2D) treatment. In the U.S, Latinos bear a disproportionate cardio-metabolic disease burden from T2D. The aim of this study was to determine levels and patterns of PA among free-living Latino adults with T2D comparing a ubiquitous consumer device with an established accelerometry method.
Participants (57 women and 31 men, BMI (kg/m2) 32.2±7.9 and 29.9±4.5, waist circumference (WC cm) 97.1±30.1 and 93.7±33.0, and HbA1C% 8.0±2.0 and 8.1±1.8, respectively) wore a research device (Actigraph, wGT3X-BT, AG) on the dominant hip and a consumer device (Fitbit Charge 2™, FB) on the non-dominant wrist to monitor daily activity for one week [outcome measures estimated by steps and energy expenditure (EE)].
AG median steps/weekday (M-F) was 6990 (range 1091-25884) compared to 9329 (288-31669) using the FB data (p≤0.01). Both devices recorded higher number of steps on weekdays compared to weekends [AG 5608 (1066-19892) and FB 7577 (1023-23603), both p≤0.05]. This corresponded to activity-related energy-expenditure of 442 (63-1821) kcals/weekday and 361 (58-1396) kcals/weekend using AG and 2344 (1135-5802) kcals/weekday and 2178 (1378-4930) kcals/weekend by FB (including resting metabolic rate). AG and FB data were highly correlated to each other for daily steps (r’s&gt;0.7, p’s&lt;0.01) but not for estimated EE. Men were more active than women on average and maintained their PA throughout the week. However, women decreased their PA on weekends (by around 1700 steps or 130 kcals/day by AG) while their weekday PA was negatively correlated with BMI and WC (p&lt;0.05). Using AG, only 2 participants reached 6,000 steps in an hour at least twice during the week and 58% never reached 3,000 steps in 30 minutes on any day of the week (a common moderate to vigorous intensity PA goal).
In conclusion, to incentivize PA in Latino adults with T2D, considerations need to be made of the timing of measurements (weekdays versus weekends), gender and technologies used.

Disclosure
W.C. Bevier: Research Support; Self; Eli Lilly and Company. N.M. Glantz: Research Support; Self; Eli Lilly and Company. C.B. Hoppe: Research Support; Self; Eli Lilly and Company. J. Morales: Research Support; Self; Eli Lilly and Company. A.J. Larez: Research Support; Self; Eli Lilly and Company. M.M. Conneely: Research Support; Self; Eli Lilly and Company. K.Y. Chen: None. D. Kerr: Advisory Panel; Self; Ascensia Diabetes Care, Novo Nordisk A/S, Sanofi. Research Support; Self; Lilly Diabetes. Stock/Shareholder; Self; Glooko, Inc.

Funding
Eli Lilly and Company
738-P: Meta’omic Analysis of Elite Athletes Identifies a Performance-Enhancing Microbe that Functions via Lactate Metabolism
Authors: KOSTIC ALEKSANDAR 
Published: June 2019

The human gut microbiome encodes a vast metabolic repertoire with direct impacts on many aspects of host physiology, yet it is unknown whether it has any bearing on physical performance or exercise. To begin to address this question, we performed a longitudinal metagenomic analysis on runners in the 2015 Boston Marathon to identify microbiome features associated with intense physical activity. The strongest microbiome feature enriched post-marathon was an increase in the abundance of the bacterial genus Veillonella. We isolated Veillonella atypica directly from the marathon runners, and found that upon inoculation in laboratory mice in an AB/BA crossover study testing treadmill runtime to exhaustion, runtime was increased 13% in a V. atypica-dependent manner. V. atypica has a preference for lactate as its primary carbon source, and we find using shotgun metagenomic analysis in a cohort of elite athletes that every differentially expressed gene family in the pathway metabolizing lactate to the short-chain fatty acid propionate is at higher relative abundance post-exercise. Using 13C3-labeled lactate in mice we demonstrate that serum lactate crosses the epithelial barrier into the lumen of the gut. We also show that intrarectal instillation of propionate is sufficient to reproduce the increased treadmill runtime performance observed with V. atypica gavage. Taken together, these studies reveal that V. atypica improves runtime via its metabolic conversion of exercise-induced lactate into propionate, thereby identifying a natural, microbiome-encoded enzymatic process that enhances athletic performance.

Disclosure
A. Kostic: Stock/Shareholder; Self; DeepBiome Therapeutics, Inc., FitBiomics, Inc.

Funding
American Diabetes Association/Pathway to Stop Diabetes (1-17-INI-13)
75-LB: Glucose Excursions over 140 mg/dL May Impact Quality of Life in Patients with Well-Managed Type 1 Diabetes
Authors: GAREY COLLEEN , HUGHES ALLYSON , BISPHAM JEOFFREY , LIU JINGWEN , FULLER LILY , NYKAZA EDWARD T. , MENO JASON A. , MCAULIFFE-FOGARTY ALICIA 
Published: June 2019

Introduction: In people with well-managed type 1 diabetes (T1D), increased glycemic variability is related to poorer quality of life (QoL). However, less is known about hyperglycemia and QoL in the same population. Clinically, mild hyperglycemia (level 1) is defined as glucose &gt;180 mg/dL and moderate (level 2) &gt;250 mg/dL; however, this does not take into account diabetes management behaviors. This analysis aimed to assess the impact of high blood glucose (HBG) on QoL in well-managed individuals using survey and CGM data.
Methods: Adults with T1D (N = 71), 68.6% female, 93.2% white, aged 44.1 years, with diabetes for 26.7 years, completed an online survey through T1D Exchange Glu and uploaded CGM data via Tidepool.
Results: In this population, the average A1c was 6.5%, with 74% of participants ≤7.0%, suggesting that, overall, they are very well-managed. On average, this cohort reported that they consider HBG to be above 189 mg/dL, but 65% consider HBG to be a value below 180 mg/dL (range 100-175 mg/dl). Because the majority of participants considered HBG to be a value below the clinically recognized cut-off, this analysis explored events &gt;140 mg/dL as a potentially meaningful cut point for HBG. Results indicated that that more events &gt;140 mg/dL in the past 7 days were associated with poorer QoL. Participants with ≥24 events above 140 mg/dL in the past 7 days had an 83% increased risk for poor QoL as defined by the WHO-5.
Conclusions: Clinically relevant cutoffs of &gt;180 mg/dL and &gt;250 mg/dL are currently used to define mild (level 1) and moderate (level 2) hyperglycemia. This data suggests that in a very well-managed population, excursions &gt;140 mg/dL have an impact on a persons’ well-being and healthcare providers need to consider how tightly managed an individual is when assessing psychosocial impacts of the disease. Limitations include small sample size and convenience sampling. Future research should further investigate the relationships of these factors in a larger sample.

Disclosure
C. Garey: None. A. Hughes: None. J. Bispham: None. J. Liu: None. L. Fuller: None. E.T. Nykaza: None. J.A. Meno: None. A. McAuliffe-Fogarty: None.
761-P: Correlation of Periodontal Inflamed Surface Area with Glycemic Status in Patients with Controlled Type 2 Diabetes Mellitus and Uncontrolled Type 2 DM With and Without Microvascular Complications
Authors: RADHAKRISHNAN CHANDNI , VADAKKEKUTTICAL ROSAMMA JOSEPH , ANIL KRISHNA , PARAMBATH FAIROZ CHERIYALINGAL 
Published: June 2019

The bidirectional relationship between periodontitis and diabetes mellitus has been well documented. Periodontitis causes systemic inflammatory burden through inflammatory mediators. The currently used tools such as Clinical Attachment Loss (CAL) and Probing Pocket Depth (PPD) to assess periodontitis are linear measurements, that do not exactly quantify the inflammatory burden of periodontitis. Periodontal Inflamed Surface Area (PISA) reflects the surface area of bleeding pocket epithelium and estimate the inflammatory burden. This study was undertaken to assess the proportion of periodontitis and correlation of PISA with glycemic status in controlled, uncontrolled type 2 diabetes mellitus (T2D) with and without micro-vascular complications. The study comprised of 180 T2D patients who were divided into three groups based on their Glycosylated Hb levels (HbA1c) (i) well controlled T2D group: (HbA1c ≤ 7%) (ii) Uncontrolled T2D group: (HbA1c &gt; 7%) without complications, and (iii) Uncontrolled T2D group: (HbA1c &gt;7%) with microvascular complications. All subjects were assessed for the periodontal parameters (Bleeding on Probing (BOP), PPD, CAL and PISA) and systemic parameters (HbA1c, FPG, and PPPG). The proportion of periodontitis among Uncontrolled T2D group without complication and Uncontrolled T2D group with micro-vascular complications was (93.4% and 96.6%) very high as compared to Well controlled T2D group (75%) (p &lt;0.001). Extent and severity of periodontitis were high in uncontrolled T2D group. Uncontrolled T2D with micro-vascular complications group attained the highest mean score for PPD, CAL, BOP and PISA. Positive correlation was found between PISA and HbA1c among the groups (r = 0.079, 0.109, 0.248 respectively). A statistically significant positive correlation has been found between PISA and HbA1c among all study subjects (r= 0.393, p &lt; 0.001).

Disclosure
C. Radhakrishnan: None. R.J. Vadakkekuttical: None. K. Anil: None. F.C. Parambath: None.
766-P: Development and Validation of a Smartphone-Based Short Food Frequency Questionnaire for Chinese Population
Authors: YANG DAIZHI , WANG CHAOFAN , LUO SIHUI , ZHENG XUEYING , LIN QIONGYAN , WEI XUEYING , YAN JINHUA , WENG JIANPING 
Published: June 2019

Objective: To develop and evaluate a smartphone-based short food frequency questionnaire.
Methods: We developed a digitalized short food frequency questionnaire adapted to the diet habit of the Chinese people. Seventy participants were recruited by quota sampling. Participants completed an FFQ face to face (1st FFQ) and a 3-day dietary record (DR) at the baseline for validation. A second FFQ (2nd FFQ) was completed 3 weeks later for reproducibility study, either face to face or on the phone.
Results: Sixty-seven participants completed the study per protocol and rendered eligible FFQs and 3-day DR. Twenty-one people were interviewed on the phone for 2nd FFQ and correlation coefficients of energy and nutrient intakes with 1st FFQ were 0.848∼0.959(all P&lt;0.01). Difference between 2nd FFQ and DR was not significant either and correlation coefficients were 0.504∼0.878(all P&lt;0.01). Correlation coefficients of energy and nutrient intakes between two FFQs ranged from 0.912 to 0.959(all P&lt;0.001). Correlation coefficients of energy and nutrient intakes between 2nd FFQ and DR ranged from 0.584 to 0.861 (all P&lt;0.01). The agreement rates of two FFQs for classifying food and nutrient intakes into same and adjacent quartiles were 65.67%∼74.63% and 25.37%∼31.34%, respectively; and between 2nd FFQ and DR, the corresponding agreement rates 38.81%-59.70% and 29.85%∼40.30%, respectively. Results of subgroup correlation analysis showed that reproducibility and validity coefficients were higher in females, well-educated group, and lower income group. We also carried out correlation analysis in diabetic patients. Correlation coefficients between two FFQs were 0.893∼0.947(P&lt;0.01), between 2nd FFQ and DR were 0.661∼0.833(all P&lt;0.01).
Conclusion: Our FFQ had satisfying reproducibility and validity in general and diabetic population and was ready to apply to remote surveys.

Disclosure
D. Yang: None. C. Wang: None. S. Luo: None. X. Zheng: None. Q. Lin: None. X. Wei: None. J. Yan: None. J. Weng: None.
769-P: Short-Term Dietary Reduction of Branched-Chain Amino Acids Reduces Meal-Induced Insulin Secretion and Modifies Microbiome Composition in Overweight Patients with Type 2 Diabetes
Authors: KARUSHEVA YANISLAVA , GEMERT THERESA VAN , STRASSBURGER KLAUS , MARKGRAF DANIEL F. , JELENIK TOMAS , MASTROTOTARO LUCIA , SIMON MARIE-CHRISTINE , ZAHARIA OANA P. , BODIS KÁLMÁN , BÄRENZ FELIX , SCHMOLL DIETER , BURKART VOLKER , MUESSIG KARSTEN , SZENDROEDI JULIA , RODEN MICHAEL 
Published: June 2019

Increased levels of branched-chain amino acids (BCAA) associate with insulin resistance and type 2 diabetes (T2D), which could result from dietary habits, gut microbiome composition or direct effects on cellular energy metabolism. We hypothesized that reduced dietary intake of BCAA improves whole body insulin sensitivity and hyperinsulinemia in patients with T2D. In a randomized, placebo-controlled, double-blinded, cross over trial, 12 metabolically well-controlled patients with T2D received an isocaloric diet (protein: 1 g/kg body weight), containing either the complete amino acid set (BCAA+) or a 60% reduction in BCAA (BCAA-) for 1 week each. Effects on glucose homeostasis were assessed from mixed meal tolerance tests (MMT) and hyperinsulinemic-euglycemic clamps (HEC, M-value), and pathways affecting insulin signaling were analyzed in muscle and adipose tissue biopsies. Microbiome composition was assessed by next generation sequencing. After the BCAA- diet, MMT-derived insulin secretion was 28% lower compared to the BCAA+ diet (p&lt;0.05). After the BCAA- diet, MMT-derived insulin sensitivity (PREDIM, the validated predicted HEC-derived M-value from meal data), turned 23% higher (p&lt;0.01), whereas HEC-derived insulin sensitivity (M-value) remained unchanged. Respiratory control ratio was 1.7-fold higher in adipose tissue (p&lt;0.05), but unchanged in skeletal muscle. Mechanistic target of rapamycin (mTOR) was downregulated by 13% in adipose tissue (p&lt;0.05). BCAA- diet was associated with a 40% increase of fecal Bacteroidetes and a 11% decrease of Firmicutes (both p&lt;0.05).
In conclusion, a short-term dietary reduction of BCAA decreases insulin secretion, increases postprandial insulin sensitivity, which may relate to adipocyte mitochondrial efficiency and altered gut microbiome composition in patients with T2D.

Disclosure
Y. Karusheva: None. T. van Gemert: None. K. Strassburger: None. D.F. Markgraf: Research Support; Self; Sanofi. T. Jelenik: None. L. Mastrototaro: None. M. Simon: None. O.P. Zaharia: None. K. Bodis: None. F. Bärenz: None. D. Schmoll: Employee; Self; Sanofi-Aventis Deutschland GmbH. V. Burkart: None. K. Muessig: None. J. Szendroedi: None. M. Roden: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Poxel SA, Servier. Board Member; Self; Eli Lilly and Company. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi. Speaker's Bureau; Self; Novo Nordisk Inc.

Funding
Sanofi Aventis Deutschland GmbH
772-P: Effect of a Low n6/n3 PUFA Diet on Intrahepatic Fat Content in Obese Adolescents
Authors: VAN NAME MICHELLE A. , CHICK JENNIFER M. , SAVOYE MARY , PIERPONT BRIDGET , GALUPPO BRITTANY , FELDSTEIN ARIEL , SANTORO NICOLA 
Published: June 2019

Recent literature suggests that the dietary imbalance between high omega-6 (n6) and low omega-3 (n3) polyunsaturated fatty acids (PUFA) intake, characteristic of the Western diet (average ratio 15:1), leads to development of fatty liver disease. We aimed to determine whether 12 weeks of a low n6/n3 PUFA ratio (4:1) normo-caloric diet might impact fatty liver (MRI assessed hepatic fat content ≥5.5%). Twenty obese adolescents with fatty liver were recruited (13.2±2.9y). Abdominal MRI and OGTT were performed at baseline and after 12-weeks intervention, the oxidized derivatives of linoleic acid (OXLAM) were measured every 4 weeks to assess compliance. Food was supplied to participants isocaloric to their pre-study diet. To control for weight change variable, weight was maintained stable throughout the study. Seventeen adolescents completed the study. After 12 weeks HFF%, decreased of about 26% (Figure 1). There was also a significant decrease in plasma concentrations of ALT (Figure 1), triglycerides (p=0.04) cholesterol (p=0.03), LDL (p=0.07) and an improvement of whole-body insulin resistance (p=0.01). There was a significant decrease of the OXLAM, 9- and 13-HODE (p=0.03 and p=0.01, respectively) and 9- and 13-oxo-ODE (p=0.05 and p=0.01, respectively). These data suggest that, independent of weight loss, a low n6/n3 PUFA diet is effective to ameliorate the metabolic phenotype of adolescents with fatty liver disease.

Disclosure
M.A. Van Name: Research Support; Self; Novo Nordisk Inc. J.M. Chick: None. M. Savoye: None. B. Pierpont: None. B. Galuppo: None. A. Feldstein: None. N. Santoro: None.

Funding
National Institutes of Health; American Heart Association